Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Jesus G. Berdeja, MD, Michael Heinrich, Shaker Dakhil, MD FACP, Stuart L. Goldberg, MD, Martha Wadleigh, MD, Rosalind Catchatourian, MD, Philip Kuriakose, MD, Jorge E. Cortes, MD, Jerald P. Radich, David A. Rizzieri, MD, Gaetano Bonifacio, MD, Ilva Dautaj, Ghulam Warsi, PhD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4048.

https://doi.org/10.1182/blood.V126.23.4048.4048

Published: 2015

Journal Articles

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Ellen K. Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Michael W Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, Michael R. Savona, MD, Ghulam Warsi, PhD, Carole S. Paley, Ilva Dautaj, Felice P. Lin, PharmD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4050.

https://doi.org/10.1182/blood.V126.23.4050.4050

Published: 2015

Journal Articles

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Noopur Raje, Robert Vescio, MD, Charles W. Montgomery, MD, Joseph T Hadala, MS, Ghulam Warsi, PhD, Solveig G. Ericson, MD, PhD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4077.

https://doi.org/10.1182/blood.V120.21.4077.4077

Published: 2012

Journal Articles

Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study.

Patrick B. Johnston, MD, PhD, Lauren Pinter-Brown, MD, Jaqueline Rogerio, MD, Ghulam Warsi, PhD, Quincy Chau, MD, MSc, Radhakrishnan Ramchandren, MD

Blood (2012) 120 (21): 2740.

https://doi.org/10.1182/blood.V120.21.2740.2740

Published: 2012

Journal Articles

Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)

Paul G. Richardson, MD, Melissa Alsina, MD, Donna M. Weber, MD, Steven E. Coutre, MD, Sagar Lonial, MD, Cristina Gasparetto, MD, Ghulam Warsi, PhD, Michael Ondovik, PharmD, MBA, Sutapa Mukhopadhyay, PhD, Susan Snodgrass, MD, Robert Schlossman, MD

Blood (2011) 118 (21): 814.

https://doi.org/10.1182/blood.V118.21.814.814

Published: 2011

Journal Articles

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Noopur Raje, MD, Robert Vescio, MD, Charles W. Montgomery, MD, Ramakrishnan Parameswaran, MD, Diep Tran, MS, Ghulam Warsi, PhD, Eliza Argonza-Aviles, RN, MSHS, Solveig G. Ericson, MD- PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 5122.

https://doi.org/10.1182/blood.V118.21.5122.5122

Published: 2011

Journal Articles

Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Patrick B. Johnston, Lauren Pinter-Brown, Jaqueline Rogerio, Ghulam Warsi, PhD, Anne Graham, Radhakrishnan Ramchandren

Blood (2011) 118 (21): 2717.

https://doi.org/10.1182/blood.V118.21.2717.2717

Published: 2011

Journal Articles

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study

Blood (2010) 116 (21): 2971.

https://doi.org/10.1182/blood.V116.21.2971.2971

Published: 2010

NARROW

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Rapid Achievement of MR 4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study.

Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Primary Analysis Results of the Z-MARK Study

Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications In Patients with Multiple Myeloma: Interim Analysis Results of the Z-MARK Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only